Navigation Links
HLTH Corporation Announces Final Results of Its Tender Offer
Date:12/3/2008

ELMWOOD PARK, N.J., Dec. 3/PRNewswire-FirstCall/ -- HLTH Corporation (Nasdaq: HLTH) announced today the final results of its tender offer to purchase up to 80,000,000 shares of its common stock at a price of $8.80 per share, which expired at 5:00 p.m., New York City time on November 25, 2008. As previously announced, HLTH exercised its right to purchase an additional 2% of its outstanding shares without extending the tender offer and has accepted for purchase 83,699,922 shares, including all "odd lots" properly tendered, at a purchase price of $8.80 per share, for a total cost of approximately $736.6 million.

Based on the final tabulation by American Stock Transfer & Trust Company, the Depositary for the tender offer, 85,821,641 shares of common stock were properly tendered and not withdrawn or tendered conditionally. HLTH has been informed by the Depositary that, after giving effect to the priority for "odd lots," the final proration factor is approximately 97.513%.

The Depositary will promptly issue payment for the shares validly tendered and accepted for purchase and will return all other shares tendered and not accepted for purchase.

Citi acted as Dealer Manager for the tender offer. Innisfree M&A Incorporated acted as Information Agent for the tender offer.

THIS PRESS RELEASE IS FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSTITUTE AN OFFER TO BUY OR THE SOLICITATION OF AN OFFER TO SELL SHARES OF HLTH CORPORATION COMMON STOCK. THE TENDER OFFER WAS MADE ONLY PURSUANT TO THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED MATERIALS THAT HLTH DISTRIBUTED TO ITS STOCKHOLDERS AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. STOCKHOLDERS AND INVESTORS SHOULD READ CAREFULLY THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND RELATED MATERIALS BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE VARIOUS TERMS OF, AND CONDITIONS TO, THE TENDER OFFER. STOCKHOLDERS AND INVESTORS MAY OBTAIN A FREE COPY OF THE TENDER OFFER STATEMENT ON SCHEDULE TO, AS AMENDED, THE OFFER TO PURCHASE, LETTER OF TRANSMITTAL AND OTHER DOCUMENTS THAT HLTH FILED WITH THE SECURITIES AND EXCHANGE COMMISSION AT THE COMMISSION'S WEBSITE AT WWW.SEC.GOV OR BY CALLING INNISFREE M&A INCORPORATED, THE INFORMATION AGENT FOR THE TENDER OFFER, TOLL-FREE AT 1-888-750-5834.

About HLTH

HLTH Corporation (Nasdaq: HLTH) owns approximately 84% of WebMD Health Corp. (Nasdaq: WBMD). WebMD is the leading provider of health information services, serving consumers, physicians, healthcare professionals, employers and health plans through its public and private online portals and health-focused publications. HLTH also owns Porex, a developer, manufacturer and distributor of proprietary porous plastic products and components used in healthcare, industrial and consumer applications.

All statements contained in this press release, other than statements of historical fact, are forward-looking statements. These statements are based on our current plans and expectations and involve risks and uncertainties that could cause actual future events or results to be different than those described in or implied by such forward-looking statements, including risks and uncertainties regarding: changes in financial markets; changes in economic, political or regulatory conditions or other trends affecting the healthcare, Internet, information technology and plastics industries; and changes in facts and circumstances and other uncertainties concerning the completion of the tender offer. Further information about these matters can be found in our Securities and Exchange Commission filings. Except as required by applicable law or regulation, we do not undertake any obligation to update our forward-looking statements to reflect future events or circumstances.

WebMD(R), WebMD Health(R) and POREX(R) are trademarks of HLTH Corporation or its subsidiaries.


'/>"/>
SOURCE HLTH Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. United American Healthcare Corporation Announces Stock Repurchase Program
2. Response Biomedical Corporation Announces Initiation of Respiratory Syncytial Virus Infection Clinical Trial
3. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
4. Providence Service Corporation Retains UBS Investment Bank as its Financial Advisor in Connection With the Sale of Certain Non-Strategic Assets
5. DURECT Corporation to Participate in Upcoming Healthcare Conferences
6. HLTH Corporation Announces Preliminary Results of Its Tender Offer
7. Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories
8. Volcano Corporation Presentation at Piper Jaffray Conference to Be Webcast
9. Craig A. Norris Appointed to Providence Service Corporation Board of Directors
10. Baxa Corporation Announces Co-Marketing Agreement With Industry Leaders Pharmacy OneSource, Inc and ClinicalIQ LLC
11. Environmental Tectonics Corporations BioMedical Systems Division Announces Additional Sales of its Baramed Monoplace Chambers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... 24, 2017 , ... The 2017 NCSL International Workshop & ... focuses on the new ISO/IEC 17025 standards. This marks the first time in ... calibration will be changed. , As an exhibitor, METTLER TOLEDO will showcase ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking ... shows that adherence rates for positive airway pressure (PAP) therapy, the most widely ...
(Date:7/24/2017)... ... July 24, 2017 , ... A Southern California-based author has released ... abuse, and how she has overcome them. “Forbidden Memories: A Memoir,” by author Michelle ... how she has risen above. , In “Memories,” readers get a firsthand look at ...
(Date:7/24/2017)... ... July 24, 2017 , ... Committed to eliminating clubfoot as ... 100,000 children in their treatment program. Clubfoot is a pervasive problem in the ... is limited or non-existent. Without intervention, these children are destined to grow up ...
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical Quality Assurance:, Roles and ... 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , Early bird pricing for ... growing demands to track and report adverse events place even greater pressure on ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... , July 14, 2017 Endo International plc (NASDAQ: ... on Tuesday, August 8, 2017.  Members of its senior management team ... markets open at 8:30 a.m. ET. The dial-in ... (866) 497-0462, International (678) 509-7598, and the passcode is 45397076. Please ... A replay of the call ...
(Date:7/12/2017)... July 12, 2017 CarpalAID is a revolutionary new product ... surgery. Carpal tunnel syndrome affects more than 8 million ... the rate of men. The common methods of treating CTS are ... uncomfortable hand braces or gloves. ... CarpalAID is a clear patch worn on ...
(Date:7/11/2017)... LINCOLNSHIRE, Ill. , July 11, 2017 /PRNewswire/ ... hematology and urinalysis diagnostic testing equipment as well ... latest innovation: a way to make quality assurance ... control processes. "Sysmex is well known for the ... SM Quality Monitor elevates quality assurance processes ...
Breaking Medicine Technology: